A different angle on all the ASCO news

| 2 Comments

Read the Forbes piece, "Are Cancer Drugs Worth The Money", for a different perspective on all the news coming out of the American Society of Clinical Oncology meeting. It begins:

ORLANDO - At the annual meeting of the American Society for Clinical Oncology, giant banners with pictures of heroic cancer patients proclaim doctors are "Personalizing Cancer Care."

But many companies seem to be maximizing cancer profit instead. Big drug companies are making big money off smaller and smaller improvements in cancer care. Newfangled cancer drugs can cost $50,000 a year, and that doesn’t mean they will add a year to the patient’s life--you might spend $50,000 for a year and extend the patient's life by only weeks.

The numbers would look better if drug companies did a better job of targeting drugs at the patients most likely to benefit. But that targeting has occurred in only a few scattered examples.

The skyrocketing costs for limited benefit are leading some experts to worry about whether the medical system has the right incentives.

"We are wasting a lot of resources treating people with treatments they don't need," says Otis Brawley, chief medical officer at the American Cancer Society.

2 Comments

Enjoy the work schwitz, although I sometimes think I need to medicate because I get so infuriated....
thanks for your work
Willie

The era of personalized medicine based on validated biomarkers is at hand. As the increasing numbers and types of cancer drugs are developed, oncologists become more and more likely to misuse them in their practice. Developing a good and clinically practical drug selection system is no less important than the discovery of new drugs or how to put them into the body.

The needed change in the 'war on cancer' will not be on the types of drugs being developed, but on the understanding of the drugs we have. The system is overloaded with drugs and underloaded with the wisdom and expertise for using them.

The single most neglected area of cancer research has been the development of methods and technologies to be matchmakers between individual cancer with individual cancer treatment. The single most neglected area of cancer treatment has been the unwillingness to utilize the matchmaker technologies which have already been developed and which are already available.

Two years ago, three federal agencies, NCI, FDA, and CMS, announced their program to try to identify biological indicators, or biomarkers, which may indicate whether a cancer patient is likely to benefit from a given anti-cancer therapy, or even whether they will suffer from certain side effects. Biomarkers were already a part of drug development, but health officials wanted to routinely incorporate those measurements into clinical trials.

We have the biomarkers for who will respond so we don't give these powerful and expensive medicines to those who won't. Just look at the Iressa/Tarceva story. A total failure of huge clinical trials because the proper patients were not selected. We should be able to detect cancer pathways with biomarkers and choose patients for a trial based on who responds very quickly to a drug. The ordinary trial system will not suffice if we are to encourage new drugs for restricted numbers of patients.

The methods of cancer medicine during the last thirty some years are coming to haunt the "one-size-fits-all" establishment. Technologies, developed over the last twenty years by private researchers, hold the key to solving some of the problems confronting a healthcare system that is seeking ways to best allocate available resources while accomplishing the critical task of matching individual patients with the treatments most likely to benefit them.

About this Entry

This page contains a single entry by Gary Schwitzer published on June 1, 2009 4:01 PM.

Another counter to conventional wisdom on early detection was the previous entry in this blog.

Profs on Twitter is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Archives

Pages

Wikio - Top of the Blogs - Health

Add to Technorati Favorites